- Clinical Trials
- April 2024
- 50 Pages
Global
From €1430EUR$1,500USD£1,226GBP
- Clinical Trials
- December 2023
- 299 Pages
Global
From €2383EUR$2,500USD£2,044GBP
- Report
- January 2022
- 200 Pages
Global
From €7148EUR$7,500USD£6,132GBP
- Report
- January 2022
- 60 Pages
Global
From €3765EUR$3,950USD£3,230GBP
- Report
- January 2022
- 60 Pages
Global
From €3765EUR$3,950USD£3,230GBP
- Report
- May 2022
- 271 Pages
Global
From €2383EUR$2,500USD£2,044GBP
- Clinical Trials
- December 2019
- 228 Pages
Global
From €2383EUR$2,500USD£2,044GBP
- Drug Pipelines
- August 2020
- 66 Pages
Global
From €1906EUR$2,000USD£1,635GBP
- Report
- August 2022
- 85 Pages
Global
From €3500EUR$3,934USD£3,107GBP
- Report
- October 2023
- 93 Pages
Global
From €3500EUR$3,934USD£3,107GBP
- Report
- May 2022
- 43 Pages
Global
From €1906EUR$2,000USD£1,635GBP
- Report
- April 2022
- 50 Pages
Global
From €1906EUR$2,000USD£1,635GBP
Oral Mucositis Drug is a type of pharmaceutical drug used to treat oral mucositis, a condition characterized by inflammation and ulceration of the mucous membranes of the mouth. It is a common side effect of chemotherapy and radiation therapy for cancer, and can cause pain, difficulty eating and drinking, and increased risk of infection. Oral Mucositis Drugs are designed to reduce inflammation, pain, and infection, and to promote healing of the mucous membranes. They may be administered topically, orally, or intravenously, depending on the severity of the condition.
Common Oral Mucositis Drugs include corticosteroids, antifungal medications, antibiotics, and antimicrobial mouthwashes. Other treatments may include topical anesthetics, laser therapy, and cryotherapy.
Companies in the Oral Mucositis Drug market include GlaxoSmithKline, Merck, Pfizer, Novartis, and Johnson & Johnson. Show Less Read more